<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03128606</url>
  </required_header>
  <id_info>
    <org_study_id>GLPG3067-CL-101</org_study_id>
    <nct_id>NCT03128606</nct_id>
  </id_info>
  <brief_title>A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG3067 in Healthy Subjects.</brief_title>
  <official_title>Assessment of Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of GLPG3067, the Combination of GLPG3067 and GLPG2222, and the Combination of GLPG3067, GLPG2222 and GLPG2737 in Healthy Female Subjects, Including a Relative Bioavailability and Food Effect Part for Single Dose of GLPG3067.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galapagos NV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a First-in-Human, Phase I, randomized, double-blind, placebo-controlled, single
      center study, evaluating single and multiple ascending oral doses of GLPG3067 and the
      combination of GLPG3067 and GLPG2222 and the combination of GLPG3067,GLPG2222 and GLPG2737
      given for 14 days in healthy women of non-childbearing potential.

      The purpose of the study is to evaluate the safety and tolerability of single ascending oral
      doses and multiple ascending oral doses of GLPG3067 given to healthy women of
      non-childbearing potential compared to placebo, as well as of multiple oral doses of the
      combination of GLPG3067/GLPG2222 compared to matching placebo for each compound and multiple
      oral doses of the combination of GLPG3067/GLPG2222/GLPG2737 compared to matching placebo for
      each compound.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 28, 2017</start_date>
  <completion_date type="Actual">February 20, 2018</completion_date>
  <primary_completion_date type="Actual">February 20, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change versus placebo in the proportion of subjects with adverse events</measure>
    <time_frame>Between screening and 14 days after the last dose</time_frame>
    <description>To assess safety and tolerability of single ascending doses, multiple ascending doses of GLPG3067 alone, or in combination with GLPG2222, or in combination with GLPG2222 and GLPG2737 versus placebo in healthy subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration of GLPG3067 (Cmax) given alone or in combination with GLPG2222 or in combination with GLPG2222 and GLPG2737</measure>
    <time_frame>Between Day 1 predose and 10 days after the last dose</time_frame>
    <description>To characterize pharmacokinetics of GLPG3067 after a single oral dose and of GLPG3067, GLPG2222, and GLPG2737 after multiple oral doses in healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve of GLPG3067 (AUC0-t) given alone or in combination with GLPG2222 or in combination with GLPG2222 and GLPG2737</measure>
    <time_frame>Between Day 1 predose and 10 days after the last dose</time_frame>
    <description>To characterize pharmacokinetics of GLPG3067 after a single oral dose and of GLPG3067, GLPG2222, and GLPG2737 after multiple oral doses in healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of 4-beta-hydroxycholesterol/cholesterol in plasma after multiple oral doses in healthy subjects</measure>
    <time_frame>Day 1 predose and Day 14</time_frame>
    <description>To assess the potential for CYP3A4 interaction with GLPG3067, GLPG3067 and GLPG2222, or GLPG3067 and GLPG2222 and GLPG2737</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration of GLPG3067 (Cmax) given alone in fed state</measure>
    <time_frame>Between Day 1 predose and 10 days after the last dose</time_frame>
    <description>To assess the relative bioavailability of GLPG3067 when given as a single dose of oral suspension or an oral tablet both administered in fed state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration in plasma observed at 24 hours post dose (C24h) of GLPG3067 given alone in fed state</measure>
    <time_frame>Between Day 1 predose and 10 days after the last dose</time_frame>
    <description>To assess the relative bioavailability of GLPG3067 when given as a single dose of oral suspension or an oral tablet both administered in fed state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve of GLPG3067 (AUC0-t) given alone in fed state</measure>
    <time_frame>Between Day 1 predose and 10 days after the last dose</time_frame>
    <description>To assess the relative bioavailability of GLPG3067 when given as a single dose of oral suspension or an oral tablet both administered in fed state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration of GLPG3067 (Cmax) given alone in fasted state</measure>
    <time_frame>Between Day 1 predose and 10 days after the last dose</time_frame>
    <description>To assess the effect of food on the pharmacokinetics of GLPG3067 when given under fasted versus fed conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration in plasma observed at 24 hours post dose (C24h) of GLPG3067 given alone in fasted state</measure>
    <time_frame>Between Day 1 predose and 10 days after the last dose</time_frame>
    <description>To assess the effect of food on the pharmacokinetics of GLPG3067 when given under fasted versus fed conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve of GLPG3067 (AUC0-t) given alone in fasted state</measure>
    <time_frame>Between Day 1 predose and 10 days after the last dose</time_frame>
    <description>To assess the effect of food on the pharmacokinetics of GLPG3067 when given under fasted versus fed conditions</description>
  </secondary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>GLPG3067 single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of GLPG3067 oral suspension at up to 6 dose levels in ascending order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo single dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of Placebo oral suspension.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG3067 oral suspension fed 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 1 of GLPG3067 oral suspension after a standardized breakfast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG3067 oral tablet fed 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 1 of GLPG3067 oral tablet after a standardized breakfast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG3067 oral tablet fasted 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 1 of GLPG3067 oral tablet after an overnight fast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG3067 oral tablet fed 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 2 of GLPG3067 oral tablet after a standardized breakfast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG3067 oral tablet fed 2 high-fat high-calorie</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 2 of GLPG3067 oral tablet after a high-fat high-calorie breakfast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG3067 multiple dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of GLPG3067 oral suspension at up to 5 dose levels in ascending order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo multiple dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple doses of Placebo oral suspension.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG3067/GLPG2222 multiple dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of GLPG3067 oral suspension combined with GLPG2222 oral tablet up to 2 dose levels in ascending order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG3067/GLPG2222 Placebo multiple dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple doses of GLPG3067 matching placebo oral suspension combined with GLPG2222 matching placebo oral tablet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG3067/GLPG2222/GLPG2737 multiple dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of GLPG3067 oral tablet combined with GLPG2222 oral tablet and GLPG2737 oral capsule at up to 2 dose levels in ascending order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG3067/GLPG2222/GLPG2737 Placebo multiple dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple doses of GLPG3067 matching placebo oral tablet combined with GLPG2222 matching placebo oral tablet and GLPG2737 matching placebo oral capsule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG3067 single dose</intervention_name>
    <description>GLPG3067 oral suspension, single ascending doses, daily</description>
    <arm_group_label>GLPG3067 single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo single dose</intervention_name>
    <description>Placebo, oral suspension, daily</description>
    <arm_group_label>Placebo single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG3067 multiple dose</intervention_name>
    <description>GLPG3067 oral suspension, multiple ascending doses, daily for 14 days</description>
    <arm_group_label>GLPG3067 multiple dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo multiple dose</intervention_name>
    <description>Placebo, oral suspension, daily for 14 days</description>
    <arm_group_label>Placebo multiple dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG3067 oral suspension</intervention_name>
    <description>GLPG3067 oral suspension, single dose, daily</description>
    <arm_group_label>GLPG3067 oral suspension fed 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG3067 oral tablet</intervention_name>
    <description>GLPG3067 oral tablet, single dose, daily</description>
    <arm_group_label>GLPG3067 oral tablet fed 1</arm_group_label>
    <arm_group_label>GLPG3067 oral tablet fasted 1</arm_group_label>
    <arm_group_label>GLPG3067 oral tablet fed 2</arm_group_label>
    <arm_group_label>GLPG3067 oral tablet fed 2 high-fat high-calorie</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG3067/GLPG2222 multiple dose</intervention_name>
    <description>GLPG3067 oral suspension and GLPG2222 oral tablet, multiple doses, daily for 14 days</description>
    <arm_group_label>GLPG3067/GLPG2222 multiple dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG3067/GLPG2222 Placebo multiple dose</intervention_name>
    <description>GLPG3067 matching placebo oral suspension and GLPG2222 matching placebo oral tablet, multiple doses, daily for 14 days</description>
    <arm_group_label>GLPG3067/GLPG2222 Placebo multiple dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG3067/GLPG2222/GLPG2737 multiple dose</intervention_name>
    <description>GLPG3067 oral tablet, GLPG2222 oral tablet and GLPG2737 oral capsule, multiple doses, daily for 14 days</description>
    <arm_group_label>GLPG3067/GLPG2222/GLPG2737 multiple dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG3067/GLPG2222/GLPG2737 Placebo multiple dose</intervention_name>
    <description>GLPG3067 matching placebo oral tablet, GLPG2222 matching placebo oral tablet and GLPG2737 matching placebo oral capsule, multiple doses, daily for 14 days</description>
    <arm_group_label>GLPG3067/GLPG2222/GLPG2737 Placebo multiple dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female subject between 18-70 years of age, inclusive, on the date of signing the
             informed consent form (ICF).

          -  Be of non-childbearing potential defined as surgically sterile (hysterectomy,
             bilateral salpingectomy and bilateral oophorectomy), or post-menopausal (at least 12
             consecutive months without menstruation, without an alternative medical cause
             [including hormone replacement therapy]).

          -  Have a body mass index between 18-30 kg/m2, inclusive.

          -  Judged by the investigator to be in good health based upon the results of a medical
             history, physical examination, vital signs, 12-lead triplicate electrocardiogram
             (ECG), and clinical safety laboratory tests prior to the initial study drug
             administration.

          -  Discontinuation of all medications (including over-the-counter and/or prescription
             medication, dietary supplements, nutraceuticals, vitamins and/or herbal supplements,
             and hormonal replacement therapy for postmenopausal subjects) except occasional
             paracetamol (maximum dose of 2 g/day and maximum of 10 g/2 weeks) at least 2 weeks
             prior to the first study drug administration.

        Exclusion Criteria:

          -  Known hypersensitivity to study drug ingredients or a significant allergic reaction to
             any drug as determined by the investigator, such as anaphylaxis requiring
             hospitalization.

          -  Clinically significant symptoms or illness in the 3 months before screening.

          -  Presence or having sequelae of gastrointestinal, liver, kidney, or other conditions
             known to interfere with the absorption, distribution, metabolism, or excretion of
             drugs.

          -  Any laboratory result considered by the investigator as clinically significant prior
             to study drug administration.

          -  Creatinine clearance ≤80 mL/min using the Cockcroft-Gault formula for subjects aged
             ≤50 years, or creatinine clearance ≤70 mL/min using the Cockcroft-Gault formula for
             subjects aged &gt;50 years. A 24-hour urine collection to determine the actual value may
             be performed to confirm creatinine clearance if required.

          -  Clinically significant abnormalities of vital signs at screening.

          -  Clinically relevant abnormalities detected on ECG regarding either rhythm or
             conduction (e.g. QT interval corrected for heart rate using Fridericia's formula
             [QTcF] &gt;470 ms) or a known long QT syndrome. A first degree heart block or sinus
             arrhythmia will not be considered as a significant abnormality.

          -  Participation in a drug, drug and device delivery system or combination, or biologic
             investigational research study within 8 weeks or 5 times the half-life of the
             investigational drug, if the half-life is known (whichever is longer) prior to initial
             study drug administration. Subjects who have been dosed previously with GLPG3067 in a
             clinical trial are allowed to participate Part 4 of this study as long as they
             completed their last follow-up visit or a washout period of 5 times the half-life of
             GLPG3067 (whichever is longer) after the last study drug administration is respected.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magdalena Petkova, MD</last_name>
    <role>Study Director</role>
    <affiliation>Galapagos NV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SGS LSS Clinical Pharmacology Unit Antwerp</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2017</study_first_submitted>
  <study_first_submitted_qc>April 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2017</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

